カテゴリ： GlobalInfoResearch, 世界, 医療/バイオ

世界の神経線維腫症1型市場2022年：市場規模予測（～2028年）

■ 英語タイトル：Global Neurofibromatosis Type 1 Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028

調査会社GlobalInfoResearch社が発行したリサーチレポート（データ管理コード：GIR22NO19455）■ 発行会社/調査会社：GlobalInfoResearch
■ 商品コード：GIR22NO19455
■ 発行日：2022年11月（※2025年版があります。お問い合わせください。）
■ 調査対象地域：グローバル
■ 産業分野：医薬品
■ ページ数：77
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（注文後2-3日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,480 ⇒換算￥528,960見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD5,220 ⇒換算￥793,440見積依頼/購入/質問フォーム
Corporate User（同一法人内共有可）USD6,960 ⇒換算￥1,057,920見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※GlobalInfoResearch社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[世界の神経線維腫症1型市場2022年：市場規模予測（～2028年）]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

神経線維腫症1型市場レポートは、世界の市場規模、地域および国レベルの市場規模、セグメント市場の成長性、市場シェア、競争環境、販売分析、国内および世界の市場プレーヤーの影響、バリューチェーンの最適化、最近の動向、機会分析、市場成長の戦略的な分析、製品発売、地域市場の拡大などに関する情報を提供します。
GlobalInfoResearchの最新の調査によると、世界の神経線維腫症1型の市場規模は2021年のxxx米ドルから2028年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。

神経線維腫症1型市場は種類と用途によって区分されます。2017年～2028年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。

種類別セグメントは次をカバーします。
・10mg、25mg

用途別セグメントは次のように区分されます。
・病院、診療所、その他

世界の神経線維腫症1型市場の主要な市場プレーヤーは以下のとおりです。
・AstraZeneca、Merck

地域別セグメントは次の地域・国をカバーします。
・北米（米国、カナダ、メキシコ）
・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア）
・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア）
・南アメリカ（ブラジル、アルゼンチン、コロンビア）
・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ）

本調査レポートの内容は計15章あります。
・第1章では、神経線維腫症1型製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。
・第2章では、主要な神経線維腫症1型メーカーの企業概要、2019年～2022年までの神経線維腫症1型の価格、販売量、売上、市場シェアを掲載しています。
・第3章では、主要な神経線維腫症1型メーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。
・第4章では、2017年～2028年までの地域別神経線維腫症1型の販売量、売上、成長性を示しています。
・第5、6章では、2017年～2028年までの神経線維腫症1型の種類別と用途別の市場規模、市場シェアと成長率を掲載しています。
・第7、8、9、10、11章では、2017年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2028年までの主要地域での神経線維腫症1型市場予測を収録しています。
・第12章では、主要な原材料、主要なサプライヤー、および神経線維腫症1型の産業チェーンを掲載しています。
・第13、14、15章では、神経線維腫症1型の販売チャネル、販売業者、顧客、調査結果と結論、付録、データソースなどについて説明します。

***** 目次(一部) *****

・市場概要
- 神経線維腫症1型の概要
- 種類別分析（2017年vs2021年vs2028年）：10mg、25mg
- 用途別分析（2017年vs2021年vs2028年）：病院、診療所、その他
- 世界の神経線維腫症1型市場規模・予測
- 世界の神経線維腫症1型生産能力分析
- 市場の成長要因・阻害要因・動向
・メーカー情報（企業概要、製品概要、販売量、価格、売上）
- AstraZeneca、Merck
・メーカー別市場シェア・市場集中度
・地域別市場分析2017年-2028年
・種類別分析2017年-2028年：10mg、25mg
・用途別分析2017年-2028年：病院、診療所、その他
・神経線維腫症1型の北米市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：アメリカ、カナダ、メキシコなど
・神経線維腫症1型のヨーロッパ市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど
・神経線維腫症1型のアジア市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど
・神経線維腫症1型の南米市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：ブラジル、アルゼンチンなど
・神経線維腫症1型の中東・アフリカ市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど
・原材料および産業チェーン
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論

The Neurofibromatosis Type 1 market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Neurofibromatosis Type 1 market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Hospitals accounting for % of the Neurofibromatosis Type 1 global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While 10 mg segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Neurofibromatosis Type 1 include AstraZeneca, Merck, , , and , etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Neurofibromatosis Type 1 market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
10 mg
25 mg
Market segment by Application can be divided into
Hospitals
Clinics
Others
The key market players for global Neurofibromatosis Type 1 market are listed below:
AstraZeneca
Merck
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Neurofibromatosis Type 1 product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Neurofibromatosis Type 1, with price, sales, revenue and global market share of Neurofibromatosis Type 1 from 2019 to 2022.
Chapter 3, the Neurofibromatosis Type 1 competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Neurofibromatosis Type 1 breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Neurofibromatosis Type 1 market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Neurofibromatosis Type 1.
Chapter 13, 14, and 15, to describe Neurofibromatosis Type 1 sales channel, distributors, customers, research findings and conclusion, appendix and data source.

*** レポート目次（コンテンツ）***

1 Market Overview
1.1 Neurofibromatosis Type 1 Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Neurofibromatosis Type 1 Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 10 mg
1.2.3 25 mg
1.3 Market Analysis by Application
1.3.1 Overview: Global Neurofibromatosis Type 1 Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Global Neurofibromatosis Type 1 Market Size & Forecast
1.4.1 Global Neurofibromatosis Type 1 Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Neurofibromatosis Type 1 Sales in Volume (2017-2028)
1.4.3 Global Neurofibromatosis Type 1 Price (2017-2028)
1.5 Global Neurofibromatosis Type 1 Production Capacity Analysis
1.5.1 Global Neurofibromatosis Type 1 Total Production Capacity (2017-2028)
1.5.2 Global Neurofibromatosis Type 1 Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Neurofibromatosis Type 1 Market Drivers
1.6.2 Neurofibromatosis Type 1 Market Restraints
1.6.3 Neurofibromatosis Type 1 Trends Analysis
2 Manufacturers Profiles
2.1 AstraZeneca
2.1.1 AstraZeneca Details
2.1.2 AstraZeneca Major Business
2.1.3 AstraZeneca Neurofibromatosis Type 1 Product and Services
2.1.4 AstraZeneca Neurofibromatosis Type 1 Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 Merck
2.2.1 Merck Details
2.2.2 Merck Major Business
2.2.3 Merck Neurofibromatosis Type 1 Product and Services
2.2.4 Merck Neurofibromatosis Type 1 Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 Neurofibromatosis Type 1 Breakdown Data by Manufacturer
3.1 Global Neurofibromatosis Type 1 Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Neurofibromatosis Type 1 Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Neurofibromatosis Type 1
3.4 Market Concentration Rate
3.4.1 Top 3 Neurofibromatosis Type 1 Manufacturer Market Share in 2021
3.4.2 Top 6 Neurofibromatosis Type 1 Manufacturer Market Share in 2021
3.5 Global Neurofibromatosis Type 1 Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Neurofibromatosis Type 1 Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Neurofibromatosis Type 1 Market Size by Region
4.1.1 Global Neurofibromatosis Type 1 Sales in Volume by Region (2017-2028)
4.1.2 Global Neurofibromatosis Type 1 Revenue by Region (2017-2028)
4.2 North America Neurofibromatosis Type 1 Revenue (2017-2028)
4.3 Europe Neurofibromatosis Type 1 Revenue (2017-2028)
4.4 Asia-Pacific Neurofibromatosis Type 1 Revenue (2017-2028)
4.5 South America Neurofibromatosis Type 1 Revenue (2017-2028)
4.6 Middle East and Africa Neurofibromatosis Type 1 Revenue (2017-2028)
5 Market Segment by Type
5.1 Global Neurofibromatosis Type 1 Sales in Volume by Type (2017-2028)
5.2 Global Neurofibromatosis Type 1 Revenue by Type (2017-2028)
5.3 Global Neurofibromatosis Type 1 Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global Neurofibromatosis Type 1 Sales in Volume by Application (2017-2028)
6.2 Global Neurofibromatosis Type 1 Revenue by Application (2017-2028)
6.3 Global Neurofibromatosis Type 1 Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America Neurofibromatosis Type 1 Sales by Type (2017-2028)
7.2 North America Neurofibromatosis Type 1 Sales by Application (2017-2028)
7.3 North America Neurofibromatosis Type 1 Market Size by Country
7.3.1 North America Neurofibromatosis Type 1 Sales in Volume by Country (2017-2028)
7.3.2 North America Neurofibromatosis Type 1 Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe Neurofibromatosis Type 1 Sales by Type (2017-2028)
8.2 Europe Neurofibromatosis Type 1 Sales by Application (2017-2028)
8.3 Europe Neurofibromatosis Type 1 Market Size by Country
8.3.1 Europe Neurofibromatosis Type 1 Sales in Volume by Country (2017-2028)
8.3.2 Europe Neurofibromatosis Type 1 Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific Neurofibromatosis Type 1 Sales by Type (2017-2028)
9.2 Asia-Pacific Neurofibromatosis Type 1 Sales by Application (2017-2028)
9.3 Asia-Pacific Neurofibromatosis Type 1 Market Size by Region
9.3.1 Asia-Pacific Neurofibromatosis Type 1 Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Neurofibromatosis Type 1 Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America Neurofibromatosis Type 1 Sales by Type (2017-2028)
10.2 South America Neurofibromatosis Type 1 Sales by Application (2017-2028)
10.3 South America Neurofibromatosis Type 1 Market Size by Country
10.3.1 South America Neurofibromatosis Type 1 Sales in Volume by Country (2017-2028)
10.3.2 South America Neurofibromatosis Type 1 Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Neurofibromatosis Type 1 Sales by Type (2017-2028)
11.2 Middle East & Africa Neurofibromatosis Type 1 Sales by Application (2017-2028)
11.3 Middle East & Africa Neurofibromatosis Type 1 Market Size by Country
11.3.1 Middle East & Africa Neurofibromatosis Type 1 Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Neurofibromatosis Type 1 Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of Neurofibromatosis Type 1 and Key Manufacturers
12.2 Manufacturing Costs Percentage of Neurofibromatosis Type 1
12.3 Neurofibromatosis Type 1 Production Process
12.4 Neurofibromatosis Type 1 Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Neurofibromatosis Type 1 Typical Distributors
13.3 Neurofibromatosis Type 1 Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer

List of Tables
Table 1. Global Neurofibromatosis Type 1 Revenue by Type, (USD Million), 2017 & 2021 & 2028
Table 2. Global Neurofibromatosis Type 1 Revenue by Application, (USD Million), 2017 & 2021 & 2028
Table 3. AstraZeneca Basic Information, Manufacturing Base and Competitors
Table 4. AstraZeneca Major Business
Table 5. AstraZeneca Neurofibromatosis Type 1 Product and Services
Table 6. AstraZeneca Neurofibromatosis Type 1 Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 7. Merck Basic Information, Manufacturing Base and Competitors
Table 8. Merck Major Business
Table 9. Merck Neurofibromatosis Type 1 Product and Services
Table 10. Merck Neurofibromatosis Type 1 Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 11. Global Neurofibromatosis Type 1 Sales by Manufacturer (2019, 2020, 2021, and 2022) & (K Units)
Table 12. Global Neurofibromatosis Type 1 Revenue by Manufacturer (2019, 2020, 2021, and 2022) & (USD Million)
Table 13. Market Position of Manufacturers in Neurofibromatosis Type 1, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2021
Table 14. Global Neurofibromatosis Type 1 Production Capacity by Company, (K Units): 2020 VS 2021
Table 15. Head Office and Neurofibromatosis Type 1 Production Site of Key Manufacturer
Table 16. Neurofibromatosis Type 1 New Entrant and Capacity Expansion Plans
Table 17. Neurofibromatosis Type 1 Mergers & Acquisitions in the Past Five Years
Table 18. Global Neurofibromatosis Type 1 Sales by Region (2017-2022) & (K Units)
Table 19. Global Neurofibromatosis Type 1 Sales by Region (2023-2028) & (K Units)
Table 20. Global Neurofibromatosis Type 1 Revenue by Region (2017-2022) & (USD Million)
Table 21. Global Neurofibromatosis Type 1 Revenue by Region (2023-2028) & (USD Million)
Table 22. Global Neurofibromatosis Type 1 Sales by Type (2017-2022) & (K Units)
Table 23. Global Neurofibromatosis Type 1 Sales by Type (2023-2028) & (K Units)
Table 24. Global Neurofibromatosis Type 1 Revenue by Type (2017-2022) & (USD Million)
Table 25. Global Neurofibromatosis Type 1 Revenue by Type (2023-2028) & (USD Million)
Table 26. Global Neurofibromatosis Type 1 Price by Type (2017-2022) & (US$/Unit)
Table 27. Global Neurofibromatosis Type 1 Price by Type (2023-2028) & (US$/Unit)
Table 28. Global Neurofibromatosis Type 1 Sales by Application (2017-2022) & (K Units)
Table 29. Global Neurofibromatosis Type 1 Sales by Application (2023-2028) & (K Units)
Table 30. Global Neurofibromatosis Type 1 Revenue by Application (2017-2022) & (USD Million)
Table 31. Global Neurofibromatosis Type 1 Revenue by Application (2023-2028) & (USD Million)
Table 32. Global Neurofibromatosis Type 1 Price by Application (2017-2022) & (US$/Unit)
Table 33. Global Neurofibromatosis Type 1 Price by Application (2023-2028) & (US$/Unit)
Table 34. North America Neurofibromatosis Type 1 Sales by Country (2017-2022) & (K Units)
Table 35. North America Neurofibromatosis Type 1 Sales by Country (2023-2028) & (K Units)
Table 36. North America Neurofibromatosis Type 1 Revenue by Country (2017-2022) & (USD Million)
Table 37. North America Neurofibromatosis Type 1 Revenue by Country (2023-2028) & (USD Million)
Table 38. North America Neurofibromatosis Type 1 Sales by Type (2017-2022) & (K Units)
Table 39. North America Neurofibromatosis Type 1 Sales by Type (2023-2028) & (K Units)
Table 40. North America Neurofibromatosis Type 1 Sales by Application (2017-2022) & (K Units)
Table 41. North America Neurofibromatosis Type 1 Sales by Application (2023-2028) & (K Units)
Table 42. Europe Neurofibromatosis Type 1 Sales by Country (2017-2022) & (K Units)
Table 43. Europe Neurofibromatosis Type 1 Sales by Country (2023-2028) & (K Units)
Table 44. Europe Neurofibromatosis Type 1 Revenue by Country (2017-2022) & (USD Million)
Table 45. Europe Neurofibromatosis Type 1 Revenue by Country (2023-2028) & (USD Million)
Table 46. Europe Neurofibromatosis Type 1 Sales by Type (2017-2022) & (K Units)
Table 47. Europe Neurofibromatosis Type 1 Sales by Type (2023-2028) & (K Units)
Table 48. Europe Neurofibromatosis Type 1 Sales by Application (2017-2022) & (K Units)
Table 49. Europe Neurofibromatosis Type 1 Sales by Application (2023-2028) & (K Units)
Table 50. Asia-Pacific Neurofibromatosis Type 1 Sales by Region (2017-2022) & (K Units)
Table 51. Asia-Pacific Neurofibromatosis Type 1 Sales by Region (2023-2028) & (K Units)
Table 52. Asia-Pacific Neurofibromatosis Type 1 Revenue by Region (2017-2022) & (USD Million)
Table 53. Asia-Pacific Neurofibromatosis Type 1 Revenue by Region (2023-2028) & (USD Million)
Table 54. Asia-Pacific Neurofibromatosis Type 1 Sales by Type (2017-2022) & (K Units)
Table 55. Asia-Pacific Neurofibromatosis Type 1 Sales by Type (2023-2028) & (K Units)
Table 56. Asia-Pacific Neurofibromatosis Type 1 Sales by Application (2017-2022) & (K Units)
Table 57. Asia-Pacific Neurofibromatosis Type 1 Sales by Application (2023-2028) & (K Units)
Table 58. South America Neurofibromatosis Type 1 Sales by Country (2017-2022) & (K Units)
Table 59. South America Neurofibromatosis Type 1 Sales by Country (2023-2028) & (K Units)
Table 60. South America Neurofibromatosis Type 1 Revenue by Country (2017-2022) & (USD Million)
Table 61. South America Neurofibromatosis Type 1 Revenue by Country (2023-2028) & (USD Million)
Table 62. South America Neurofibromatosis Type 1 Sales by Type (2017-2022) & (K Units)
Table 63. South America Neurofibromatosis Type 1 Sales by Type (2023-2028) & (K Units)
Table 64. South America Neurofibromatosis Type 1 Sales by Application (2017-2022) & (K Units)
Table 65. South America Neurofibromatosis Type 1 Sales by Application (2023-2028) & (K Units)
Table 66. Middle East & Africa Neurofibromatosis Type 1 Sales by Region (2017-2022) & (K Units)
Table 67. Middle East & Africa Neurofibromatosis Type 1 Sales by Region (2023-2028) & (K Units)
Table 68. Middle East & Africa Neurofibromatosis Type 1 Revenue by Region (2017-2022) & (USD Million)
Table 69. Middle East & Africa Neurofibromatosis Type 1 Revenue by Region (2023-2028) & (USD Million)
Table 70. Middle East & Africa Neurofibromatosis Type 1 Sales by Type (2017-2022) & (K Units)
Table 71. Middle East & Africa Neurofibromatosis Type 1 Sales by Type (2023-2028) & (K Units)
Table 72. Middle East & Africa Neurofibromatosis Type 1 Sales by Application (2017-2022) & (K Units)
Table 73. Middle East & Africa Neurofibromatosis Type 1 Sales by Application (2023-2028) & (K Units)
Table 74. Neurofibromatosis Type 1 Raw Material
Table 75. Key Manufacturers of Neurofibromatosis Type 1 Raw Materials
Table 76. Direct Channel Pros & Cons
Table 77. Indirect Channel Pros & Cons
Table 78. Neurofibromatosis Type 1 Typical Distributors
Table 79. Neurofibromatosis Type 1 Typical Customers
List of Figures
Figure 1. Neurofibromatosis Type 1 Picture
Figure 2. Global Neurofibromatosis Type 1 Revenue Market Share by Type in 2021
Figure 3. 10 mg
Figure 4. 25 mg
Figure 5. Global Neurofibromatosis Type 1 Revenue Market Share by Application in 2021
Figure 6. Hospitals
Figure 7. Clinics
Figure 8. Others
Figure 9. Global Neurofibromatosis Type 1 Revenue, (USD Million) & (K Units): 2017 & 2021 & 2028
Figure 10. Global Neurofibromatosis Type 1 Revenue and Forecast (2017-2028) & (USD Million)
Figure 11. Global Neurofibromatosis Type 1 Sales (2017-2028) & (K Units)
Figure 12. Global Neurofibromatosis Type 1 Price (2017-2028) & (US$/Unit)
Figure 13. Global Neurofibromatosis Type 1 Production Capacity (2017-2028) & (K Units)
Figure 14. Global Neurofibromatosis Type 1 Production Capacity by Geographic Region: 2022 VS 2028
Figure 15. Neurofibromatosis Type 1 Market Drivers
Figure 16. Neurofibromatosis Type 1 Market Restraints
Figure 17. Neurofibromatosis Type 1 Market Trends
Figure 18. Global Neurofibromatosis Type 1 Sales Market Share by Manufacturer in 2021
Figure 19. Global Neurofibromatosis Type 1 Revenue Market Share by Manufacturer in 2021
Figure 20. Neurofibromatosis Type 1 Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2021
Figure 21. Top 3 Neurofibromatosis Type 1 Manufacturer (Revenue) Market Share in 2021
Figure 22. Top 6 Neurofibromatosis Type 1 Manufacturer (Revenue) Market Share in 2021
Figure 23. Global Neurofibromatosis Type 1 Sales Market Share by Region (2017-2028)
Figure 24. Global Neurofibromatosis Type 1 Revenue Market Share by Region (2017-2028)
Figure 25. North America Neurofibromatosis Type 1 Revenue (2017-2028) & (USD Million)
Figure 26. Europe Neurofibromatosis Type 1 Revenue (2017-2028) & (USD Million)
Figure 27. Asia-Pacific Neurofibromatosis Type 1 Revenue (2017-2028) & (USD Million)
Figure 28. South America Neurofibromatosis Type 1 Revenue (2017-2028) & (USD Million)
Figure 29. Middle East & Africa Neurofibromatosis Type 1 Revenue (2017-2028) & (USD Million)
Figure 30. Global Neurofibromatosis Type 1 Sales Market Share by Type (2017-2028)
Figure 31. Global Neurofibromatosis Type 1 Revenue Market Share by Type (2017-2028)
Figure 32. Global Neurofibromatosis Type 1 Price by Type (2017-2028) & (US$/Unit)
Figure 33. Global Neurofibromatosis Type 1 Sales Market Share by Application (2017-2028)
Figure 34. Global Neurofibromatosis Type 1 Revenue Market Share by Application (2017-2028)
Figure 35. Global Neurofibromatosis Type 1 Price by Application (2017-2028) & (US$/Unit)
Figure 36. North America Neurofibromatosis Type 1 Sales Market Share by Type (2017-2028)
Figure 37. North America Neurofibromatosis Type 1 Sales Market Share by Application (2017-2028)
Figure 38. North America Neurofibromatosis Type 1 Sales Market Share by Country (2017-2028)
Figure 39. North America Neurofibromatosis Type 1 Revenue Market Share by Country (2017-2028)
Figure 40. United States Neurofibromatosis Type 1 Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 41. Canada Neurofibromatosis Type 1 Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 42. Mexico Neurofibromatosis Type 1 Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 43. Europe Neurofibromatosis Type 1 Sales Market Share by Type (2017-2028)
Figure 44. Europe Neurofibromatosis Type 1 Sales Market Share by Application (2017-2028)
Figure 45. Europe Neurofibromatosis Type 1 Sales Market Share by Country (2017-2028)
Figure 46. Europe Neurofibromatosis Type 1 Revenue Market Share by Country (2017-2028)
Figure 47. Germany Neurofibromatosis Type 1 Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 48. France Neurofibromatosis Type 1 Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 49. United Kingdom Neurofibromatosis Type 1 Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 50. Russia Neurofibromatosis Type 1 Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 51. Italy Neurofibromatosis Type 1 Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 52. Asia-Pacific Neurofibromatosis Type 1 Sales Market Share by Region (2017-2028)
Figure 53. Asia-Pacific Neurofibromatosis Type 1 Sales Market Share by Application (2017-2028)
Figure 54. Asia-Pacific Neurofibromatosis Type 1 Sales Market Share by Region (2017-2028)
Figure 55. Asia-Pacific Neurofibromatosis Type 1 Revenue Market Share by Region (2017-2028)
Figure 56. China Neurofibromatosis Type 1 Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 57. Japan Neurofibromatosis Type 1 Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 58. Korea Neurofibromatosis Type 1 Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 59. India Neurofibromatosis Type 1 Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. Southeast Asia Neurofibromatosis Type 1 Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. Australia Neurofibromatosis Type 1 Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. South America Neurofibromatosis Type 1 Sales Market Share by Type (2017-2028)
Figure 63. South America Neurofibromatosis Type 1 Sales Market Share by Application (2017-2028)
Figure 64. South America Neurofibromatosis Type 1 Sales Market Share by Country (2017-2028)
Figure 65. South America Neurofibromatosis Type 1 Revenue Market Share by Country (2017-2028)
Figure 66. Brazil Neurofibromatosis Type 1 Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 67. Argentina Neurofibromatosis Type 1 Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 68. Middle East & Africa Neurofibromatosis Type 1 Sales Market Share by Type (2017-2028)
Figure 69. Middle East & Africa Neurofibromatosis Type 1 Sales Market Share by Application (2017-2028)
Figure 70. Middle East & Africa Neurofibromatosis Type 1 Sales Market Share by Region (2017-2028)
Figure 71. Middle East & Africa Neurofibromatosis Type 1 Revenue Market Share by Region (2017-2028)
Figure 72. Turkey Neurofibromatosis Type 1 Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 73. Egypt Neurofibromatosis Type 1 Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 74. Saudi Arabia Neurofibromatosis Type 1 Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. South Africa Neurofibromatosis Type 1 Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 76. Manufacturing Cost Structure Analysis of Neurofibromatosis Type 1 in 2021
Figure 77. Manufacturing Process Analysis of Neurofibromatosis Type 1
Figure 78. Neurofibromatosis Type 1 Industrial Chain
Figure 79. Sales Channel: Direct Channel vs Indirect Channel
Figure 80. Methodology
Figure 81. Research Process and Data Source


*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 世界の神経線維腫症治療薬市場2022年：市場規模予測（～2028年）
  • 世界の三次元電気生理ナビゲーションシステム市場2022年：市場規模予測（～2028年）
  • 世界の経口用レボチロキシンナトリウム市場2022年：市場規模予測（～2028年）
  • 世界のデジタル歯科用 X 線センサー市場2022年：市場規模予測（～2028年）
  • 世界の使い捨て型歯科滅菌針市場2022年：市場規模予測（～2028年）
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(GIR22NO19455 )"世界の神経線維腫症1型市場2022年：市場規模予測（～2028年）" (英文：Global Neurofibromatosis Type 1 Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028)はGlobalInfoResearch社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。